SEC Company Response from NORTHWEST BIOTHERAPEUTICS (NWBO) — Oct 21, 2022
NORTHWEST BIOTHERAPEUTICS INC
Date: Oct. 21, 2022 · CIK: 0001072379 · Accession: 0001104659-22-110601
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-267933
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Attention: Daniel Crawford Re: Request for Acceleration of Effectiveness of Registration Statement on Form S-3 (File No. 333-267933)
Dear Mr. Crawford:
Northwest Biotherapeutics, Inc., a Delaware corporation (the “Company”), respectfully requests pursuant to Rule 461 under the Securities Act of 1933, as amended, that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-267933) (the “Registration Statement”) be accelerated and that it be declared effective October 25, 2022 at 4:00 p.m. Eastern time, or as soon as practicable thereafter, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time.
Please direct any questions regarding this filing to Brian Lane of Gibson, Dunn & Crutcher LLP at (202) 887-3646.
Very truly yours,
/s/ Linda F. Powers
Show Raw Text
CORRESP 1 filename1.htm Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 October 21, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Daniel Crawford Re: Request for Acceleration of Effectiveness of Registration Statement on Form S-3 (File No. 333-267933) Dear Mr. Crawford: Northwest Biotherapeutics, Inc., a Delaware corporation (the “Company”), respectfully requests pursuant to Rule 461 under the Securities Act of 1933, as amended, that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-267933) (the “Registration Statement”) be accelerated and that it be declared effective October 25, 2022 at 4:00 p.m. Eastern time, or as soon as practicable thereafter, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. Please direct any questions regarding this filing to Brian Lane of Gibson, Dunn & Crutcher LLP at (202) 887-3646. Very truly yours, /s/ Linda F. Powers Linda F. Powers Chief Executive Officer of Northwest Biotherapeutics, Inc. cc: Brian Lane, Gibson, Dunn & Crutcher LLP